“Considering the cost and quality of life to the individual, we believe our study has important implications for management of age-related sarcopenia.”...
SAN ANTONIO (March 15, 2023) — A new software tool developed by Texas Biomedical Research Institute and collaborators can help scientists and vaccine...
A recently patented genome editing tool called PASTE holds genuine promise for expanding the universe of treatable genetic diseases. The post PASTE, Don’t...
After Novartis acquired AveXis, executives from the leading gene therapy biotech shuffled off to form new startups looking to repeat their Zolgensma story...
Biotech startup Locanabio has laid off 30% of its workforce, portending a limited scope going forward for the gene therapy developer, backed with more...
Insilico Medicine, a clinical-stage biotech company powered by generative AI, today announces that China National Medical Products Administration (NMPA)...
From my analysis of Zynerba Pharmaceuticals Inc. (ZYNE) and the extremely optimistic analyst stock price projections stated above, I think Zynerba would...
Dealing with the seismic effects of the COVID-19 pandemic, the biopharma industry continues to break new ground during a transformative era of product...
Remember how good 2020 was for biotech venture numbers? Now hold that thought. Bioregnum Opinion Column by John Carroll Diving into the numbers for life...
What Fauci Knew About Vaccine Ineffectiveness... And When Authored by Jeffrey A. Tucker via The Epoch Times (emphasis ours), What if Anthony...
Bayer’s first challenge is the post-COVID-19 treatment landscape, in which patients have foregone routine screenings and cancer care worldwide—the...
Plant-based Covid-19 vaccine developer Medicago shut down this week with little fanfare. And its two subsidiaries, Medicago R&D and Medicago USA, are...
Coldspot-guided antibody discovery (a screening approach that focuses on portions of the SARS-CoV-2 spike glycoprotein that are both functionally relevant...
The coronavirus keeps evolving, and in so doing it evades our immune defenses. But does the entire coronavirus evolve, or do some portions remain unchanged?...
In this final instalment of IQVIA EMEA Thought Leadership’s Nine for 2023 three-part series, focusing on issues that The post Nine for 2023, part three:...
Biotech Vaxxas has announced a partnership agreement with the 2017-established Coalition for Epidemic Preparedness Innovations (CEPI), in order The post...
Waiting until the very last minute, former US Commerce Secretary Wilbur Ross’ special purpose acquisition company has found a business to buy: a biotech...
Ben Hargreaves speaks to Liberate Bio, a company that is hoping to address the delivery issues that could The post Taking an ‘upside-down’ approach...
Regulatory authorities in the US are investigating a possible link between the new Pfizer/BioNTech bivalent COVID-19 booster vaccine The post US eyes link...
Rats and mice have been the backbone of biomedical research for decades — including research to understand cancer and pioneer new treatments. Credit:...
Crossing the blood-brain barrier is a familiar challenge in therapeutic applications. And it is increasingly recognized as a challenge for imaging applications,...
At a recent industry event, the 14th Annual Bioprocessing Summit in Boston, scientists discussed a variety of advances in gene therapy manufacturing. To...
Hot penny stocks to watch with news this week. The post 5 Hot Penny Stocks To Watch This Week With Big News appeared first on Penny...
Insilico Medicine (“Insilico”), a clinical stage, end-to-end artificial intelligence (AI)-driven drug discovery company, held the launch ceremony...
Alex Zhavoronkov, PhD, founder and CEO of Insilico Medicine (“Insilico”), a clinical stage end-to-end artificial intelligence (AI)-driven drug discovery...
Catherine Isted has stepped down as chief executive of UK biotech ReNeuron with immediate effect, with board member The post Restructuring announced at...
Lithuania offers a range of government support for biotech companies, including 20 years of corporate tax relief for capital investments and seven Free...
There’s been huge progress in treatments for blood cancer in recent years – but drawbacks of expensive CAR-T The post After a slow start for expensive...
It seems like a slam dunk. Why not repurpose already approved or well-studied drug candidates for conditions where treatments are desperately needed? Wouldn’t...
A review of the latest executive moves in the pharma industry over the past several months.